Narcolepsy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Narcolepsy – Pipeline Review, H2 2017’, provides an overview of the Narcolepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Narcolepsy

The report reviews pipeline therapeutics for Narcolepsy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Narcolepsy therapeutics and enlists all their major and minor projects

The report assesses Narcolepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Narcolepsy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Narcolepsy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Avadel Pharmaceuticals Plc

Bioprojet SCR

Evotec AG

F. Hoffmann-La Roche Ltd

H.A.C. Pharma

Heptares Therapeutics Ltd

Jazz Pharmaceuticals Plc

Ono Pharmaceutical Co Ltd

OptiNose US Inc

Reset Therapeutics Inc

Sanofi

SK Biopharmaceuticals Co Ltd

Taisho Pharmaceutical Holdings Co Ltd

Theranexus SAS

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Narcolepsy - Overview 6

Narcolepsy - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Narcolepsy - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Narcolepsy - Companies Involved in Therapeutics Development 21

Avadel Pharmaceuticals Plc 21

Bioprojet SCR 21

Evotec AG 21

F. Hoffmann-La Roche Ltd 22

H.A.C. Pharma 22

Heptares Therapeutics Ltd 23

Jazz Pharmaceuticals Plc 23

Ono Pharmaceutical Co Ltd 24

OptiNose US Inc 24

Reset Therapeutics Inc 25

Sanofi 25

SK Biopharmaceuticals Co Ltd 25

Taisho Pharmaceutical Holdings Co Ltd 26

Theranexus SAS 26

Narcolepsy - Drug Profiles 28

(flecainide acetate + modafinil) - Drug Profile 28

arbaclofen - Drug Profile 30

JZP-258 - Drug Profile 31

JZP-386 - Drug Profile 32

JZP-507 - Drug Profile 33

LGD-3437 - Drug Profile 34

mazindol - Drug Profile 35

mazindol CR - Drug Profile 36

ONO-4127 - Drug Profile 38

OPN-021 - Drug Profile 39

pentylenetetrazol - Drug Profile 40

pitolisant - Drug Profile 41

RO-5256390 - Drug Profile 44

SAR-110068 - Drug Profile 45

SKL-N05 - Drug Profile 46

Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile 52

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile 53

Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile 54

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 55

sodium oxybate - Drug Profile 56

sodium oxybate ER - Drug Profile 59

TS-091 - Drug Profile 61

YNT-185 - Drug Profile 62

Narcolepsy - Dormant Projects 63

Narcolepsy - Discontinued Products 64

Narcolepsy - Product Development Milestones 65

Featured News & Press Releases 65

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Number of Products under Development for Narcolepsy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Narcolepsy – Pipeline by Avadel Pharmaceuticals Plc, H2 2017

Narcolepsy – Pipeline by Bioprojet SCR, H2 2017

Narcolepsy – Pipeline by Evotec AG, H2 2017

Narcolepsy – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Narcolepsy – Pipeline by H.A.C. Pharma, H2 2017

Narcolepsy – Pipeline by Heptares Therapeutics Ltd, H2 2017

Narcolepsy – Pipeline by Jazz Pharmaceuticals Plc, H2 2017

Narcolepsy – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Narcolepsy – Pipeline by OptiNose US Inc, H2 2017

Narcolepsy – Pipeline by Reset Therapeutics Inc, H2 2017

Narcolepsy – Pipeline by Sanofi, H2 2017

Narcolepsy – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017

Narcolepsy – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017

Narcolepsy – Pipeline by Theranexus SAS, H2 2017

Narcolepsy – Dormant Projects, H2 2017

Narcolepsy – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Narcolepsy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports